|
| N-(5-chloro-2-methylphenyl)-2-(4-oxo-3(4H)-quinazolinyl)acetamide |
|
Mycobacterium |
Immune modulation |
Preclinical (in vitro) |
Karanja CW, et al. 2021. ACS Infect Dis |
|
| 3-{[4-(dimethylamino)-2-pyridin-3-yl-5,8-dihydropyrido[3,4-d]pyrimidin-7(6H)-yl]carbonyl}phenol |
|
Mycobacterium |
Immune modulation |
Preclinical (in vitro) |
Karanja CW, et al. 2021. ACS Infect Dis |
|
| 2-phenyl-2,3-dihydrophthalazine-1,4-dione |
|
Shigella |
VirF |
Preclinical (in vitro) |
Hurt JK, et al. 2010. J Biomol Screen |
|
| 5-chloro-N-(3-cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)-2-(ethylsulfonyl)-4-pyrimidinecarboxamide |
|
Shigella |
VirF |
Preclinical (in vitro) |
Emanuele AA, et al. 2014. J Antibiot (Tokyo); Emanuele AA, et al. 2015. PLoS One |
|
| Pyridazinone, 2 |
|
Staphylococcus |
Others |
Preclinical (in vitro) |
Suree N, et al. 2009. Bioorg Med Chem |
|
| 5-chloro-N-(4-chlorobenzyl)-N-(1,1-dioxidotetrahydrothien-3-yl)-2-(ethylsulfonyl)pyrimidine-4-carboxamide |
|
Vibrio |
Stress survival |
Preclinical (in vitro) |
Stanbery L, et al. 2017. Drug Des Devel Ther |
|
| 1,3-dioxo-2-[4-(4-phenylquinazolin-2-yl)phenyl]-2,3-dihydro-1H-isoindole-5-carboxylic acid |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Eriksson J, et al. 2012. Adv Exp Med Biol |
|
| 1,6-dimethyl-3-(thiophen-2-yl)pyrimido[5,4-e][1,2,4]triazine-5,7(1H,6H)-dione |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| 3-(4-Chloro-phenyl)-1,6-dimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| 5-{3-bromo-4-[(4-nitrobenzyl)oxy]benzylidene}pyrimidine-2,4,6(1H,3H,5H)-trione |
|
Yersinia |
TTSS secreted effectors |
Preclinical (in vitro) |
Hu X, et al. 2013. Bioorg Med Chem Lett |
|
| | | |
